|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 October 2000, Vol. 96, No. 8, pp. 2717-2722
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Cell dose and speed of engraftment in placental/umbilical cord
blood transplantation: graft progenitor cell content is a better
predictor than nucleated cell quantity
Anna Rita Migliaccio,
John
W. Adamson,
Cladd E. Stevens,
N. Ludy Dobrila,
Carmelita M. Carrier, and
Pablo Rubinstein
From the Department of Clinical Biochemistry, Istituto
Superiore di Sanita, Rome, Italy; the Blood Research Institute, Blood
Center of Southeastern Wisconsin, Milwaukee, WI; and the Placental
Blood Program, New York Blood Center, New York, NY.
There is evidence that the total cellular content of
placental cord blood (PCB) grafts is related to the speed of
engraftment, though the total nucleated cell (TNC) dose is not a
precise predictor of the time of neutrophil or platelet engraftment. It
is important to understand the reasons for the quantitative association
and to improve the criteria for selecting PCB grafts by using indices more precisely predictive of engraftment. The posttransplant course of
204 patients who received grafts evaluated for hematopoietic colony-forming cell (CFC) content among 562 patients reported previously were analyzed using univariate and multivariate life-table techniques to determine whether CFC doses predicted hematopoietic engraftment speed and risk for transplant-related events more accurately than the TNC dose. Actuarial times to neutrophil and platelet engraftment were shown to correlate with the cell dose, whether estimated as TNC or CFC per kilogram of recipient's weight. CFC association with the day of recovery of 500 neutrophils/µL, measured as the coefficient of correlation, was stronger than that of
the TNC (R =  0.46 and 0.413, respectively). In multivariate tests
of speed of platelet and neutrophil engraftment and of probability of
posttransplantation events, the inclusion of CFC in the model displaced
the significance of the high relative risks associated with TNC. The
CFC content of PCB units is associated more rigorously with the major
covariates of posttransplantation survival than is the TNC
and is, therefore, a better index of the hematopoietic content of
PCB grafts.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Moscardo, J. Sanz, L. Senent, S. Cantero, J. de la Rubia, P. Montesinos, D. Planelles, I. Lorenzo, J. Cervera, J. Palau, et al.
Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies
Haematologica,
June 1, 2009;
94(6):
827 - 832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Iori, W. Arcese, F. Milano, E. Calabrese, G. F. Torelli, W. Barberi, M. G. Mascolo, L. De Felice, M. Screnci, B. Lucarelli, et al.
Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: a long-term follow-up
Haematologica,
August 1, 2007;
92(8):
1051 - 1058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Section on Hematology/Oncology and Section on Alle
Cord Blood Banking for Potential Future Transplantation
Pediatrics,
January 1, 2007;
119(1):
165 - 170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Grewal, J. N. Barker, S. M. Davies, and J. E. Wagner
Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?
Blood,
June 1, 2003;
101(11):
4233 - 4244.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Stevens, J. Gladstone, P. E. Taylor, A. Scaradavou, A. R. Migliaccio, J. Visser, N. L. Dobrila, C. Carrier, M. Cabbad, P. Wernet, et al.
Placental/umbilical cord blood for unrelated-donor bone marrow reconstitution: relevance of nucleated red blood cells
Blood,
September 18, 2002;
100(7):
2662 - 2664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Wagner, J. N. Barker, T. E. DeFor, K. S. Baker, B. R. Blazar, C. Eide, A. Goldman, J. Kersey, W. Krivit, M. L. MacMillan, et al.
Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
Blood,
August 13, 2002;
100(5):
1611 - 1618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, L. Bianchi, C. Cellai, F. Paoletti, R. A. Rana, R. Lorenzini, G. Migliaccio, and A. R. Migliaccio
Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1low mice)
Blood,
July 30, 2002;
100(4):
1123 - 1132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. Sanz, S. Saavedra, D. Planelles, L. Senent, J. Cervera, E. Barragan, C. Jimenez, L. Larrea, G. Martin, J. Martinez, et al.
Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies
Blood,
October 15, 2001;
98(8):
2332 - 2338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
